SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of December 2023
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in its charter)
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On December 18, 2023, Can-Fite BioPharma Ltd. issued a press release entitled “Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan”. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|Press Release dated December 18, 2023
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Date: December 18, 2023
|/s/ Motti Farbstein
|Chief Executive Officer and Chief Financial Officer